Personal CFO Solutions LLC Cuts Position in Astrazeneca Plc $AZN

Personal CFO Solutions LLC trimmed its stake in Astrazeneca Plc (NYSE:AZN) by 47.8% in the 1st quarter, HoldingsChannel reports. The fund owned 10,517 shares of the company’s stock after selling 9,628 shares during the quarter. Personal CFO Solutions LLC’s holdings in Astrazeneca were worth $2,074,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Triumph Capital Management purchased a new position in Astrazeneca in the third quarter valued at about $25,000. MV Capital Management Inc. bought a new position in Astrazeneca in the fourth quarter worth about $26,000. Bangor Savings Bank lifted its position in shares of Astrazeneca by 102.7% during the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after buying an additional 154 shares during the last quarter. Eagle Bay Advisors LLC purchased a new stake in shares of Astrazeneca during the fourth quarter valued at about $30,000. Finally, YANKCOM Partnership bought a new stake in shares of Astrazeneca in the 4th quarter valued at about $31,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

• Negative Sentiment: AstraZeneca said its Wainua drug failed to meet the main goal in a Phase III trial for a serious heart disease, a setback that hit investor confidence because the medicine had been one of the company’s more closely watched pipeline assets. Reuters article on Wainua trial failure
• Negative Sentiment: The trial failure was described as a significant valuation hit, with reports saying the stock dropped nearly 10% in London trading and erased roughly £19 billion from AstraZeneca’s market value. Proactive Investors article on valuation impact
• Neutral Sentiment: Reuters reported earlier in the week that AstraZeneca and Daiichi Sankyo were nearing a UK pricing deal for the breast cancer drug Enhertu, which could support the company’s commercial outlook if finalized. Reuters article on Enhertu pricing deal
• Neutral Sentiment: AstraZeneca also announced a new respiratory-drug licensing deal with Sino Biopharmaceutical worth up to $1.9 billion, including $200 million upfront, underscoring continued pipeline investment even as the market focuses on the trial miss. Reuters article on Sino Biopharma licensing deal

Astrazeneca Price Performance

Shares of AZN stock opened at $189.41 on Thursday. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The firm has a market capitalization of $293.76 billion, a price-to-earnings ratio of 28.44, a PEG ratio of 1.57 and a beta of 0.24. The stock’s 50-day simple moving average is $184.14 and its 200-day simple moving average is $188.61.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. The firm had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. As a group, equities analysts forecast that Astrazeneca Plc will post 10.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Bank of America reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st. UBS Group reissued a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Weiss Ratings lowered shares of Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 18th. Finally, Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. Fourteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Astrazeneca presently has an average rating of “Moderate Buy” and an average price target of $211.00.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.